Compositions to control oral microbial oxidation-reduction (Eh) levels

ABSTRACT

The present invention relates to an oral composition containing a zinc compound containing free available zinc ion and at least one stabilized or stable Eh raising compound distributed in an oral vehicle. The present invention further relates to a method of inhibiting the formation of sulfur containing anions and preventing a reduction in the Eh of the oral cavity. A method of reducing oral malodor and gingivitis and periodontitis is also provided by this invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is the U.S. national phase of International ApplicationNo. PCT/US97/19598 filed Oct. 23, 1997, which is a continuation-in-partof U.S. Appln. Ser. No. 08/736,356 filed Oct. 23, 1996; abandoned theentire disclosure of which are herein incorporated by reference.

FIELD OF INVENTION

The present invention provides oral compositions comprising a zinccompound containing free available zinc and at least one stabilized orstable E_(h) raising compound distributed in an oral vehicle. Thepresent invention is further directed to a method of inhibiting theformation of anionic sulfur species in the oral cavity and preventing alowering of the E_(h) of the oral cavity. A method of simultaneouslyreducing oral malodor, gingivitis and periodontitis by preventing orreducing oral putrefaction is also provided by this invention.

BACKGROUND OF THE INVENTION

The hard and soft tissues of the mouth are covered with microbialpopulations that contain bacteria with different metabolic capabilities.The Gram-positive bacteria within these microbial populations readilycatabolize carbohydrates to produce acids which attack the hard tissuesof the oral cavity, resulting in the formation of dental caries lesions(cavities). In contrast, the Gram-negative bacteria, especially theanaerobes readily metabolize various amino acids contained in salivary(and to lesser extent other) peptides and proteins in the oral cavity toform end-products which favor the formation of oral malodor andperiodontitis. This process of peptide, protein and amino aciddegradation by the mouth bacteria is referred to as oral bacterialputrefaction. The mixture of malodorous compounds produced by theGram-negative anaerobic bacteria during putrefactive degradation ofproteins, peptides and amino acids include hydrogen sulfide, methylmercaptan, and dimethyl sulfide (formed from the sulfur containing aminoacids cysteine, cystine and methionine); indole and skatole (formedduring the metabolism of tryptophan); cadaverine and putrescine(produced from lysine and ornithine); and butyrate and valerate(produced from the metabolism of other amino acids). The production ofthese malodorous compounds in the oral cavity results in a conditioncommonly referred to as oral malodor.

Hydrogen sulfide, methyl mercaptan, butyrate and propionate areputrefaction end-products that also have cell and tissue alteringnon-inflammatory roles in the periodontitis process. Hydrogen sulfideand methylmercaptan are compounds particularly effective in facilitatingthe oral epithelium penetrability of toxins and other large molecularweight compounds produced by Gram-negative bacteria, and leading to theinflammation and tissue degradation characteristics of gingivitis andperiodontitis. Gingivitis is a condition in which the gingiva is red,swollen and bleeding. If left untreated, gingivitis may develop intoperiodontitis, a condition characterized by destruction of theperiodontium, including epithelial attachment loss, periodontal membraneand ligament destruction, and loss of gingiva and alveolar bone. Severeperiodontitis resulting in deep periodontal pockets may ultimatelyresult in tooth loss.

Previous studies have largely focused on the use of germicidal agents totreat gingivitis-periodontitis and oral malodor. Until the findings bythe present invention, previous studies have not recognized thatgingivitis-periodontitis and oral malodor arise from a common process,oral bacterial putrefaction; also that this putrefaction can beinhibited by simultaneously lowering the ability of the oral bacteria toreduce the oxidation-reduction potential (E_(h)) of the oral cavity andat the same time, raising the existing E_(h) to where the oralenvironmental E_(h) is not conducive to oral putrefaction and oraldisease production.

The metabolism and growth of anaerobic bacteria in the oral cavity isfavored when the E_(h) is lowered. The present invention has discoveredthat the oxidation-reduction potential (E_(h)) is a key regulatingfactor in oral bacterial putrefaction. The lowering of the E_(h) of theoral cavity has been found to occur in two steps, a depletion of oxygenfollowed by the generation of electron rich compounds. The presentinvention has discovered from studies on the isolation and catabolism bythe oral bacteria of nitrogenous substrates in human saliva that theprimary compounds responsible for lowering the E_(h) of the oral cavityare non-volatile sulfur containing anions derived largely from cysteineand cystine (Table 1). These include the anionic sulfur species, sulfide(S⁼), hydrogen sulfide (HS⁻) and methyl mercaptan (CH₃S⁻). Such anionsfavor an ecological environment of reduction (lower E_(h)) that enablesthe Gran-negative anaerobic bacteria in the mouth to grow, engage inoral putrefaction and produce electron-rich compounds leading to andmaintaining a prolonged lowering of the E_(h) of the oral cavity and theundesirable conditions of oral malodor, gingivitis and periodontitis. Alower E_(h) favors the oral bacterial putrefaction process whereas ahigher E_(h) is inhibitory.

TABLE 1 Lowest E_(h) reached with the common amino acids when incubatedwith the mixed bacteria in salivary sediment. E_(h) (millivolts) aminoacids Group A Group B Group C alanine 100 arginine 25 asparagine 70aspartic 80 cysteine 20 cystine −10 glutamic 30 glutamine 100 histidine70 isoleucine 115 leucine 110 lysine 95 methionine 20 ornithine 55phenylalanine 100 proline 100 serine 115 threonine 110 tryptophan 85tyrosine 40 valine 105 salivary supematant −25; water control 142

The present invention provides compounds that simultaneously (i) inhibitthe formation of these electron-rich compounds and thereby prevent theE_(h) from falling to harmful levels and (ii) react with anyelectron-rich compounds formed and by thus neutralizing them, raise theE_(h) to safer levels. It has been surprisingly discovered in accordancewith the present invention that an oral composition containing a zinccompound capable of providing free available zinc and a stabilized orstable E_(h) raising compound can effectively prevent the lowering ofthe E_(h). This is crucial to preventing oral bacterial putrefaction,the metabolic process that is the basis and that results in thedevelopment of both oral malodor and gingivitis-periodontitis.

Zinc compounds, hydrogen peroxide, and chlorine dioxide have each beenused as therapeutic agents in oral compositions to destroy harmfulbacteria involved in oral malodor and gingivitis-periodontitisformation. Previous studies where zinc has been identified as havinganti-microbial and anti-plaque effects have made no distinction betweenzinc compounds where the zinc is freely available and where it is not.(See for example, U.S. Pat. No. 4,289,755 to Dhabhar). The zinc speciesis an important element of this invention, since free available zinc(zinc ion) within the oral cavity is required to inhibit the E_(h)lowering capability of a pathogenic, putrefactive microbiota. Zinccompounds used in the compositions previously described includecompounds where zinc is not freely available. Zinc that is bound orcomplexed to various ligands and zinc species that have a low solubilityand form precipitates are prevented from reacting with the E_(h)lowering enzymes and products produced by the putrefactive microbiotaand hence are poorly suited for the purposes of this invention.

The solubility for zinc compounds vary as shown in the table below.

Solubility of selected zinc compounds Solubility Compound Formula (g/100cc) zinc chloride ZnCl₂ 432 @ 25° C. zinc citrate Zn₃(C₆H₅O₇)₂ slightlysoluble zinc acetate Zn(C₂H₃O₃)₂ 30 @ 20° C. zinc lactate Zn(C₃H₅O₃)₂5.7 @ 15° C. zinc salicylate Zn(C₇H₅O₃)₂ 5 @ 20° C. zinc sulfate ZnSO₄soluble zinc oxide ZnO 0.00016 @ 29° C. zinc nitrate ZnNO₃)₂ infinitelysoluble

Data are from the Handbook of Chemistry and Physics, Chemical RubberCompany, 67th Edition CRC Press, Boca Raton, Fla., 1986-87.

It is evident from this table that the amount of zinc that will besoluble and available in the oral cavity for controlling pathogenicmicrobiota will vary considerably. Those zinc compounds that provide lowlevels of zinc ion in solution, such as zinc oxide, are unsuitable forthe present invention. This distinction between the various zinccompounds was not recognized prior to this invention. In essence, inorder to inhibit the E_(h) from falling to harmful levels, it isessential that the zinc ions are freely available.

Previous studies have also identified hydrogen peroxide and chlorinedioxide as germicidal agents. The chlorine dioxide is usually derivedfrom the chlorite ion. Hydrogen peroxide owes its germicidal activity tooxygen release and formation of free radicals which provides chemicaland mechanical mechanisms for killing oral anaerobic bacteria andcleaning wounds and removing tissue and other debris from inaccessibleareas (such as between the teeth). The release of oxygen from hydrogenperoxide is particularly pronounced in the presence of catalase, organicmatter, metals and metal compositions. In this invention, this isinhibited from happening by use of chloride ion, so that the peroxidewill serve as an E_(h) raising compound rather than as a germicidalagent. U.S. Pat. Nos. 5,104,644, 5,174,990 and 5,310,546 to Douglasdescribe the use of hydrogen peroxide as such a germicidal agent.Specifically in the oral composition described by Douglas, hydrogenperoxide releases molecular oxygen in the presence of tissue catalaseand peroxidase to act against the oral anaerobic bacteria. Previousstudies do not stabilize the hydrogen peroxide so that it does not breakdown.

The oral composition described herein acts as an E_(h) raising compoundrather than one that results in formation of breakdown products. In thisinvention, degrading these species to produce a germicidal effect, isavoided. The hydrogen peroxide in the composition described herein isstabilized using chloride ion, an acidic pH, and avoiding mixing it withzinc ion until just before use.

Chlorine dioxide is an oxyhalogen compound widely used in industry fordisinfection and control of bacterial biofouling. It is also used tocontrol taste, odor, oxidation of metal ions and color removal in otherapplications. Several studies have described using chlorine dioxide asan antimicrobial agent in mouth rinse applications. For example, U.S.Pat. No. 4,696,811 to Ratcliff describes a method and composition todestroy malodorous compounds; Patent No. UK 2290233A to Drayson andButcher describes compositions for tooth whitening. Others includeinventions where the oxidizing and germicidal capabilities of chlorinedioxide are activated by forming chlorine dioxide just prior to use. Themain reason chlorine dioxide is generated in this way is becausechlorine dioxide is an unstable gas at room temperature (boiling pointof 11° C.) and is sensitive to decomposition by visible and ultravioletlight. In previous studies, the chlorine dioxide is commonly generatedfrom the chlorite ion by acidification. It is usually provided as sodiumchlorite buffered to a pH around 7 to 8 and above, and as such, referredto as stabilized chlorine dioxide (U.S. Pat. Nos. 4,689,215 and4,837,009 to Ratcliff, Patent No. UK 2290233A to Drayson and Butcher andPatent No. WO 95/27472 to Richter). Chlorine dioxide like hydrogenperoxide above, is typically generated for the purpose of killing mouthbacteria. Where acidification of chlorite is carried out, the levels ofchlorine dioxide produced are usually adequate for its germicidalpurpose. But in those compositions where chlorine dioxide is stabilizedas sodium chlorite at neutral or alkaline pH, formation of chlorinedioxide from chlorite ion is a relatively slow process. Accordingly,very little chlorine dioxide is available within the oral cavity as anantibacterial agent in these compositions. In contrast, in thecompositions herein, chlorite ions are not used as germicidal agents.Instead they are used as effective and stable E_(h) raising compounds,if their degradation to chlorine dioxide is avoided.

In previous inventions, chlorite ion use involves provision (rather thanremoval) of electrons to enable chlorite ion disproportionation andformation of the bacteriocidal compound, chlorine dioxide, a processstimulated by acid addition. The oxidation-reduction change involveschange in oxidation state from +3 to +4. On the other hand, whenchlorite acts as an E_(h) raising compound as in the invention herein,its oxidation state decreases from +3 to −1. Reduction of chlorite ionis to chloride ion after going through a series of reactions involvingvarious intermediates. What is evident from this analysis is that thechlorite ion is capable of acting as either an oxidizing or as areducing agent depending upon the reaction conditions. Few compoundsshow such multi-step, and hence atypical redox buffer effects.Nonetheless, this enables them to counter or resist along with zinc ionthe kinds of changes in the E_(h) level that enable oral putrefaction toflourish and be suitable for this invention.

Using sodium chlorite as an E_(h) raising compound rather than as asource of chlorine dioxide is very important, because chlorine dioxideat elevated levels combines with certain amino acids to producecompounds that are potentially mutagenic. Therefore, inhibition orprevention of significant chlorine dioxide formation from sodiumchlorite is desirable and preferred and contra-indicated is theutilizing of sodium chlorite to generate large amounts of chlorinedioxide therefrom in order to kill enough bacteria to have significantoral effects.

A neutral pH and above is essential for chlorite ion stability and toavoid chlorine dioxide formation. Also, chloride ion is useful foradditional stabilization of the sodium chlorite where there is anydecrease in the pH. This is because chloride ion is produced whenchlorite becomes chlorous acid and disproportionation of chlorous acidoccurs

 5HClO₂→4ClO₂+Cl⁻+H⁺+2H₂O

This reaction is inhibited by mass action when chloride ion is provided.

Hydrogen peroxide like sodium chlorite behaves as an E_(h) raisingcompound in that it can also readily react as either an oxidizing or areducing agent. Analogous to the chlorine dioxide/chlorite/chloridesystem is the molecular oxygen/hydrogen peroxide/water system wherechlorite ion and hydrogen peroxide are similarly positioned asoxidation-reduction intermediates. In previous studies, the peroxide isused to generate oxygen and/or oxygen reactive species to kill the oralbacteria involved in oral disease. As found for chlorite ion, peroxidein this invention functions as an E_(h) raising compound by removing theexcess electrons of putrefaction and producing hydroxyl ions rather thangiving up electrons and undergoing disproportionation as in previouspatents.

The disproportionation reaction of hydrogen peroxide

2H₂O₂→2H₂O+O₂

is very slow under ordinary conditions but rapid in the presence of theenzymes, catalase and peroxidase, found in certain of the bacteria inthe oral cavity. Once again, hydrogen peroxide is a species likechlorite ion that is thermodynamically unstable with respect todisproportionation and can function as an intermediate inoxidation-reduction reactions. Further and once again, the chloride ioninhibits the disproportionation of hydrogen peroxide but does so throughinhibition of catalase.

The oxygen-oxygen single bond in hydrogen peroxide is one of the weakestcovalent bonds known. It is easily broken indicating that it readilyaccepts electrons and as a result is able to produce hydroxyl ions.Alternatively, hydrogen peroxide is converted into the stable oxygenmolecule. Previous studies have shown, using ¹⁸O labeled hydrogenperoxide, that the oxygen produced is derived entirely from the peroxidespecies and not from water. This suggests that the breakdown of peroxidedoes not involve the breaking of the O—O bond but provides electrons toan appropriate oxidizing agent. H₂O₂ when used as an E_(h) raisingcompound is not used as a source for molecular oxygen.

Recent studies by Douglas (U.S. Pat. Nos. 5,104,644, 5,174,990, and5,310,546) have described oral compositions combining zinc chloride andhydrogen peroxide to treat gingivitis-periodontitis. U.S. Pat. No.5,174,990 describes a mouth rinse containing zinc chloride and hydrogenperoxide. In these Douglas patents, it is necessary to counter theinstability prior to use of the formulations described, which is causedlargely because of the presence of zinc metal. To aid in stabilizationof zinc, ligands that bind well to zinc such as citrate andlaurylsulfate are added. However, these additions reduce theavailability of free zinc, especially when these ligands are present athigh ligand to zinc ratios. The mouth rinses in U.S. Pat. Nos. 5,174,990and 5,310,546 have zinc chloride concentration ranging from 0.005% to0.1% and a hydrogen peroxide concentration ranging from 0.25% to 0.65%.In the absence of ligands that bind zinc, zinc ion at these zincchloride levels range in concentration between 0.002% and 0.047%.Moreover, recent studies have shown that hydrogen peroxide at theconcentrations described therein are degraded by oral bacterial catalaseand are not effective in vivo. Ryan and Kleinberg (1995) Archs. oralBiol., 40, 753-763. Accordingly, to compensate for the rapid breakdownof hydrogen peroxide by catalase, use of higher concentrations ofhydrogen peroxide (1% or above) is necessary. At hydrogen peroxideconcentrations above 3.0 to 3.5%, studies have shown that hydrogenperoxide can be harmful to the soft tissues of the oral cavity. Thus,for an oral composition containing hydrogen peroxide to be effective asa therapeutic and at the same time not harm the soft or hard tissues ofthe oral cavity or be harmful if swallowed, its concentration needs tobe between about 1% and 3%.

In contrast, the oral compositions discovered in this invention containsufficient chloride ions to inhibit catalase hydrolysis of the peroxide,thereby enabling peroxide to remain intact even at lower peroxide levelsthan 1% and for the peroxide to serve as an E_(h) raising compound whereformation of toxic products from peroxide are avoided.

Many reactions involving hydrogen peroxide in solution result in theproduction of free radical species, such as HO₂ and OH. These areeffective agents for killing bacteria and such formation is a basis forthe use of hydrogen peroxide as a disinfectant. Transition metal-ioncatalyzed decomposition of hydrogen peroxide can readily give rise tothe formation of free radicals. The destabilizing effects of zinc areavoided in this invention by using a two compartment approach wherecombination with zinc compound is provided just prior to use to ensuremaximum availability of free zinc. The compositions described hereinresult in a synergism between the zinc ions, the peroxide used as anE_(h) raising compound and the chloride ions. This two compartmentsystem is a more desirable and effective approach than oral compositionspreviously described.

Methylene blue has been used as an E_(h) raising compound. It readilyaccepts electrons and in this way helps prevent the electronaccumulation that produces the low E_(h) that favors oral putrefaction.In U.S. Pat. No. 5,087,451 to Wilson and Harvey, methylene blue is usedto inhibit periodontitis. The beneficial effect of methylene blue aloneis significantly less than achieved when used in conjunction with zincion as with the compositions of this invention.

SUMMARY OF THE INVENTION

The present invention is directed to oral compositions containing a zinccompound where zinc ion is freely available and at least one stabilizedor stable E_(h) raising compound distributed in an oral vehicle. In oneembodiment, the oral compositions contain a zinc compound containingfreely available zinc ions, hydrogen peroxide and a chloride ioncontaining compound. In another embodiment, the oral compositioncontains a zinc ion compound and an oxyhalogen compound. A furtherembodiment of this invention includes an oral composition containing azinc ion compound and methylene blue.

The present invention is further directed to a method of inhibiting theformation of anionic sulfur species and thereby preventing a lowering ofthe E_(h) of the oral cavity. Specifically, the method comprisesdelivering into the oral cavity a therapeutically effective amount of anoral composition containing a free available zinc compound and at leastone stabilized or stable E_(h) raising compound distributed in an oralvehicle.

A further embodiment of the present invention is a method of reducingboth oral malodor and gingivitis-periodontitis comprising deliveringinto the oral cavity a therapeutically effective amount of an oralcomposition containing a zinc ion compound and at least one stabilizedor stable E_(h) raising compound.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the relation between zinc ion concentration and the rate atwhich the oral bacteria are able to produce volatile sulfur compoundsand associated sulfur anions from cysteine. Inhibition is exponentialand occurs maximally once the zinc ion concentration reaches about 0.2%.

FIG. 2 shows the changes in the E_(h) during an incubation of mixed oralbacteria and (i) salivary supernatant (ii) glucose (iii) salivarysupernatant and glucose and (iv) a water control.

FIG. 3 shows the changes in E_(h) during an incubation of mixed oralbacteria and salivary supernatant with (i) zinc chloride (ii) hydrogenperoxide and (iii) zinc chloride ion plus hydrogen peroxide. A controlincubation containing mixed oral bacteria with salivary supernatant isalso shown. Hydrogen peroxide by itself loses some of its ability toinhibit the E_(h) lowering due to hydrogen peroxide degradation bybacterial catalase during the incubation.

FIG. 4 shows the mean E_(h), odor index, volatile sulfur compound (VSC)level and the level of indole/skatole produced in samples taken atintervals in a 4 hour period after rinsing with a mouth rinse containingzinc chloride (0.08%), hydrogen peroxide (1%) and NaCl (2.9%). VSClevels are measured with an instrunent called the Halimeter.

FIG. 5 shows the concentration of volatile sulfur compounds and theE_(h) in vivo following rinsing with cysteine (VSC and E_(h) responses)before and after a mouth rinse containing zinc chloride at 6 mM (0.08%).

FIG. 6 shows the concentration of volatile sulfur compounds and theE_(h) in vivo following rinsing with cysteine (VSC and E_(h) responses)before and after a mouth rinse containing zinc chloride at 6 mM (0.08%),hydrogen peroxide at 1% and sodium chloride at 500 mM (2.9%).

FIG. 7 shows the concentration of volatile sulfur compounds and theE_(h) in vivo following rinsing with cysteine (VSC and E_(h) responses)before and after a mouth rinse containing zinc chloride at 6 mM (0.08%)and sodium chlorite at 0.5%.

FIG. 8 shows the concentration of volatile sulfur compounds in vivofollowing rinsing with cysteine (VSC and E_(h) responses) before andafter a mouth rinse containing sodium chlorite at 0.1%.

FIG. 9 shows the concentration of volatile sulfur compounds in vivofollowing rinsing with cysteine (VSC and E_(h) responses) before andafter a mouth rinse containing sodium chlorite at 0.1% and zinc chlorideat 6 mM (0.08%).

DETAILED DESCRIPTION OF THE INVENTION

The essential components and their relevant proportions in thecompositions of the invention are set forth below. All patents,publications and test methods mentioned herein are incorporated byreference.

The present invention relates to an oral composition containing a zincion compound where a high concentration of free available zinc isprovided and at least one E_(h) raising compound distributed in an oralvehicle. A zinc ion compound as defined by the present invention is acompound containing freely available zinc ions capable of inhibiting thelowering of the oral cavity E_(h). Important in this regard isinhibiting the breakdown of cysteine or cystine from saliva, mucosaltissues (especially the tonguie) and foods by the oral bacteria. Freelyavailable zinc ions are ions that are not bound. Zinc compounds presentin the oral compositions of this invention include, for example, zincchloride, zinc acetate, zinc lactate, zinc salicylate, zinc sulfate, andzinc nitrate. In one embodiment of the present invention, the zinccompound is zinc chloride. The concentration of zinc ion in the oralcomposition may range from about 0.02% to about 0.2%. In a preferredembodiment, the zinc ion concentration ranges from about 0.04% to about0.12%.

A stabilized E_(h). raising compound as defined herein is a compoundcapable of directly or indirectly raising the E_(h) of the oral cavity.Examples of E_(h) raising compounds include, for example, hydrogenperoxide, oxyhalogen species such as sodiumn chlorite and biologicallycompatible oxidation-reduction (redox) buffers such as methylene blue.Additional examples of E_(h) raising compounds include commonfermentable sugars such as glucose, galactose, fructose, maltose,lactose and sucrose. These compounds when metabolized by oral bacteriaand in particular, the oral streptococci, in the presence of oxygenproduce, inter alia, hydrogen peroxide.

The concentration of the E_(h) raising compound in the oral compounds ofthis invention may range from about 0.1% to about 3.0% by weight of thecomposition. In a preferred embodiment, the concentration of the E_(h)raising compound is about 0.1% to about 1.0%. When the E_(h) raisingcompound is hydrogen peroxide or a fermentable sugar, a chloride ioncontaining compound is added to the oral composition in an amountsufficient to inhibit catalase in the oral cavity from breaking down thehydrogen peroxide. The chloride ion containing compound is a compoundcapable of inhibiting the catalas activity in the oral cavity. Suitablechloride ion containing compounds include alkali metal chloride saltsand alkali earth metal chloride salts such as, for example, NaCl andCaCl₂. Generally, the concentration of the chloride ion containingcompound in the oral composition ranges from about 0.5% to about 2.5% byweight of the composition. Since some oral microbiota produce hydrogenperoxide in the presence of fermentable sugars, chloride ions are alsoadded to make it more effective.

In one embodiment of this invention the zinc compound is zinc chloride,the E_(h) raising compound is hydrogen peroxide and the chloride ioncontaining compound is sodium chloride. In another embodiment of thisinvention, the oral composition contains zinc chloride, a fermentablesugar and sodium chloride. In a further embodiment of this invention,the oral composition contains zinc chloride and the oxyhalogen speciessodium chlorite and with or without sodium chloride. A furtherembodiment of the present invention consists of oral compositionscontaining zinc chloride and methylene blue with or without sodiumchloride.

We have discovered that the pH of the oral compositions of the presentinvention is specific to the zinc compound and E_(h) raising compoundcombination used. When the E_(h) raising compound is hydrogen peroxide,the preferred pH of the oral compositions generally ranges from about3.0 to about 6.0. In one embodiment, the pH ranges from about 3.5 toabout 4.5. An acidic pH has two desirable effects. First, an acidic pHensures availability of the zinc ion since zinc ion above a pH of about6.0 combines with hydroxyl ions in solution to form poorly soluble zinchydroxide, thereby making zinc ion unavailable. Second an acidic pHconverts sulfur anions to the acidic forms which result in a higherE_(h). In the case of hydrogen sulfide, because hydrogen sulfide isvolatile, its formation serves as an effective means of getting rid ofelectrons carried by sulfide anion that are particularly conducive tolowering the E_(h). Third, catalase degradation of hydrogen peroxide isinhibited at an acidic pH. An acidic pH and the presence of chlorideion, ensures that the hydrogen peroxide in the composition is notdegraded with storage and hence retains its effectiveness.

On the other hand, when the E_(h) raising compound is the oxychloride,sodium chlorite, a pH between about 3.0 and 6.0 is unsuitable for thestability of sodium chlorite during its storage. At acidic pH, unstableand less desirable chlorine dioxide is produced. To be of use for thepurpose of this invention, the pH of the sodium chlorite during storageneeds to be between about 7.0 and about 8.5 where it is most stable. Theinstability of zinc ion at a pH of 6.0 and above and the instability ofchlorite at a pH of about 6.0 and below necessitates the two being keptseparate in a two compartment system until ready for use. When broughtinto contact with each other immediately before mixture use, thepreferred pH is between about 5.5 and about 6.0. Addition of chlorideion as sodium chloride and/or as part of zinc chloride, providesstability along with synergistic activity. The pH of the oralcompositions described herein can be controlled with acids such ashydrochloric and benzoic and with base such as sodium hydroxide. A Inaddition to the zinc-peroxide-chloride ion composition, thezinc-oxyhalogen composition, and the zinc-methylene blue composition,the oral compositions described in accordance with the present inventionmay contain any conventional ingredient for the particular oralcomposition. For example, liquid mouthwashes may contain a solvent suchas distilled or deionized water, and ethanol; a sweetening agent such assorbitol, mannitol, xylitol, saccharin and aspartame; and a flavoringagent such as peppermint oil, and spearmint oil. (See U.S. Pat. Nos.4,226,851; 4,209,754; 4,289,755; and 5,104,644). Because of theformulation difficulties associated with zinc ion instability at aboutpH 6.0 and above resulting from the forming of poorly soluble zinchydroxide and the instabilities of many E_(h) raising compounds such assodium chlorite and hydrogen peroxide, two compartment systems where thezinc ion compound and the E_(h), raising compound are in respectivecompartments but can be mixed immediately prior to use are preferred. Anexample of a two compartment composition for zinc chloride and sodiumchlorite is shown in Table 2.

Dentifrices may contain, for example, a conventional abrasive such ascalcium pyrophosphate, aluminum hydroxide, resins, insoluble alkalimetal metaphosphates and silica in a standard amount of 20-60% wt.; abinder such as hydroxyethyl cellulose, xanthin gum and sodiumcarboxymethylcellulose in a standard amount of 0.5-5.0% wt.; a foamingagent such as sodium lauryl sulfate, sodium coconut monoglyceridesulfonate and sodium-N-methyl-N-palmitoyl tauride in a standard amountof 0.5-3.0% wt.; a flavoring agent; a sweetening agent; an antisepticagent and any other ingredient required for the particular formulation.(See U.S. Pat. No. 5,372,802). Two compartment delivery systems arepreferred. Tables and powders may contain, for example, a vehicle suchas lactose or mannitol; a binder such as corn starch or carboxymethylcellulose; and a disintegrator, once more in two compartment deliverysystems.

The present invention is also directed to a method of inhibiting theformation of sulfur containing anions in the oral cavity and preventinga lowering of the E_(h) of the oral cavity by delivering into the oralcavity a therapeutically effective amount of an oral compositioncontaining, a zinc ion compound and at least one E_(h) raising compounddistributed in an oral vehicle. As defined by the present invention,sulfur containing anions include for example, sulfide (S⁼), hydrogensulfide anion (HS⁻) and methyl mercaptan anion (CH₃S⁻). Atherapeutically effective amount of oral composition is an amountsufficient to inhibit the formation of sulfur containing anions andprevent a lowering of the E_(h) of the oral cavity. For example, atherapeutically effective amount of the oral composition in a dentifriceor mouth rinse may range from approximately 0.5% to approximately 5% byweight and preferably 2% to 3% by weight of the composition.

Acceptable oral vehicles include, for example, any conventional oraldelivery system, such as dental care products, food products and chewinggum. Examples of dental care products include for example, dentifrices,topical solutions or pastes, mouthwashes in the form of liquids,powders, gels or tablets, and dental flosses. Examples of food productswhich contain the oral compositions described herein include, forexample, lozenges and confectioneries.

The present invention is further directed to a method of reducing oralmalodor, gingivitis and periodontitis by delivering into the oral cavitya therapeutically effective amount of an oral composition containing azinc ion compound and at least one E_(h) raising compound distributed inan acceptable oral vehicle. As defined by the present invention, atherapeutically effective amount of an oral composition is an amountsufficient to raise the E_(h) of the oral cavity to normal levels andprevent or reduce oral malodor, gingivitis and periodontitis. Forexample, a therapeutically effective amount of an oral composition is anamount sufficient to reduce or prevent the formation of malodorouscompounds such as hydrogen sulfide and the growth of harmfulGram-negative anaerobic bacteria which may cause gingivitis andperiodontitis. A therapeutically effective amount of the oralcomposition in a dentifrice or mouthwash may range from approximately0.5% to approximately 5% by weight and preferably about 2% to about 3%by weight of the composition.

The present invention further provides an article of manufacturecomprising a packaging material and the oral compositions describedherein contained within said packaging material, wherein said oralcomposition is effective in preventing and/or reducing any decrease inthe E_(h), oral putrefaction and development of oral malodor, gingivitisand periodontitis and wherein said packaging material contains a labelthat indicates that said oral composition is effective in raising theE_(h), and reducing oral putrefaction, oral malodor, gingivitis andperiodontitis. The packaging material used to contain the oralcompositions can comprise glass, plastic, metal or any other suitablyinert material. For example, a dentifrice containing the oralcomposition of the present invention may be contained in a collapsibletube, typically aluminum, lined lead or plastic or a squeeze, pump orpressurized dispenser for measuring out the contents or in a tearablesachet.

In order to further illustrate the present invention, the experimentsdescribed in the following examples were carried out. It should beunderstood that the invention is not limited to the specific examples orthe details described therein. The results obtained from the experimentsdescribed in the examples are shown in the accompanying table andfigures.

EXAMPLE I

This Example demonstrates the ability of salivary supernatant to lowerthe E_(h) and the ability of glucose to act as an E_(h) raising compoundto raise the E_(h) in the salivary sediment system model developed byKleinberg (1967 and 1970) Archs. oral Biol., 12:1457-1473; Advances oralBiol. (Volume 4) New York, N.Y. Academic Press pp. 49-50 (see FIG. 2).This model utilizes the mixed oral bacteria collected in the salivarysediment obtained from whole saliva by centrifugation. Extensive studieshave shown that this system behaves metabolically like dental plaque(Singer et al. (1983) Archs. oral Biol. 28:29-35; Wijeyeweera andKleinberg (1989 a and b) Archs. oral Biol. 34:43-64; Salako andKleinberg (1992) Archs. oral Biol. 37:821-829; Ryan and Kleinberg (1995)Archs. oral Biol. 40:743-752). This model is recognized in the art as aneffective proxy to study the microbial metabolic and related biochemicalprocesses of the oral cavity. The ability of the different amino acidsavailable from salivary peptides and proteins to lower the E_(h) in thesalivary sediment system is shown in Table 1.

To collect salivary sediment and salivary supernatant for the assay,saliva stimulated by chewing paraffin wax was expectorated intotest-tubes chilled in cracked ice. The donors had not brushed theirteeth for 24 hours prior to collection. The donors were also instructedto fast for at least 12 hours to provide stimulated whole saliva whichcontains a minimal level of endogenous carbohydrate. (Kleinberg andJenkins (1964) Archs. oral Biol, 9:493-516). Following collection, thesaliva was centrifuged at 1740×g for 15 minutes and the supernatant wassubsequently removed by pipette and kept on ice until the assay was run.Next, the sediment was washed three times with ice cold distilled waterto remove any residual salivary supernatant. The washed salivarysediment was chilled in crushed ice until the assay was run. Prior toincubating the samples and running the assay, the washed salivarysediment was re-suspended in distilled water to a final concentration of50 per cent (V/V).

To assay the ability of various amino acids and salivary supernatant toproduce a lowering of the E_(h), incubation tubes were preparedcontaining the following: 16.7% (V/V) salivary sediment, 60 mM phosphatebuffer and either 33.3% (V/V) salivary supernatant or 3 mM amino acid. Acontrol tube contained sediment and water. All incubation mixturepreparations were done with the test-tubes chilled in cracked ice untilthey were transferred, to a water bath for incubation at 37° C. for 24hours. Measurements were taken at the following time intervals: 0 and 30min and 1, 2, 3, 8 and 24 hours.

The oxidation-reduction potential (E_(h)) was determined in eachincubation mixture using a platinum electrode and a potassium chloridesalt bridge leading to a calomel reference electrode connected to a pHmeter used as a millivoltmeter. All E_(h) measurements were related tothe standard hydrogen electrode by adding the value 242 millivolts tothe reading made with this electrometric system. The lowest E_(h)reached with each amino acid is shown in Table 1. The correspondinglowest E_(h) levels reached with salivary supernatant and the watercontrol are shown at the bottom of the table. The E_(h) with supernatantfalls to the lowest E_(h) and is only matched by the amino acid,cystine. Of the various amino acids tested, the sulfur containing aminoacids—cystine, cysteine and methionine (Group C) showed the lowestE_(h); arginine, glutamic, ornithine and tyrosine (Group B) showed nextlowest; and the remainder (Group A) showed the highest E_(h) levels.Fractionation experiments of salivary supernatant identified smallpeptides with cystine as the constituent mainly responsible for theE_(h) lowering activity of salivary supernatant.

EXAMPLE II

A similar type of in vitro experiment as in Example I was carried out toassay the ability of (i) zinc chloride, (ii) hydrogen peroxide, and(iii) zinc chloride and hydrogen peroxide, to prevent a fall in theE_(h) of the oral cavity. Incubation tubes were prepared containing16.7% sediment, 60 mM phosphate buffer, and (i) zinc chloride at aconcentration of 6.0 mM (0.08%), (ii) hydrogen peroxide at aconcentration of 0.5%, or (iii) zinc chloride at a concentration of 6.0mM and hydrogen peroxide at a concentration of 0.5%. A tube was preparedcontaining salivary sediment and salivary supernatant only (watercontrol). FIG. 2 shows the E_(h) of the mixtures during incubation at37° C. over a 24-hour time period.

As shown in FIG. 3, zinc chloride and hydrogen peroxide alone, or incombination, significantly raised the E_(h) of the incubation mixturecompared to the salivary supernatant plus salivary sediment control. Thecontrol incubation mixture containing only sediment and supernatantshowed a rapid and extensive lowering of the E_(h). The incubationmixtures with zinc chloride alone and hydrogen peroxide alone, showedsome decrease in the E_(h). Hydrogen peroxide alone progressively lostsome of its E_(h) reducing ability as there was no chloride presentunlike in zinc chloride to inhibit its degradation by catalase. Den zincchloride and hydrogen peroxide were combined in the incubation, only aslight decrease in the E_(h) occurred. The results in this exampledemonstrated the ability of a composition containing zinc chloride andhydrogen peroxide to reduce the decrease in the E_(h), and therebyreduce the oral putrefaction that is conducive to the development oforal malodor, gingivitis and periodontitis.

EXAMPLE III

This example shows the ability of the zinc ion-peroxide-chloride ioncompositions of the present invention to retard or reduce the E_(h)lowering ability of the oral bacteria and their ability to producemalodor. As shown in Example II, hydrogen peroxide can have aninhibitory effect on odor production by the mixed bacteria that comprisethe microflora of the salivary sediment system. However, it will bedifficult for peroxide to persist in this system or in dento-gingival ortongue plaque in situ because their microfloras contain bacteria thathave exceptionally high catalase and peroxidase activities. (Ryan andKleinberg (1995) Archs. oral Biol. 40:743-752). Consequently, forperoxide to be effective in the mouth, it is necessary to inhibit thiscatalase activity. Otherwise, peroxide levels well over 1% would benecessary to reduce the oral malodor and this concentration can beharmful to the oral soft tissues. An agent presently documented to beinhibitory of catalase activity is chloride ion.

This assay examined the effects of rinsing with a combination of ZnCl₂,H₂O₂ and NaCl on the E_(h) and odor producing activity of the oralbacteria. The oral rinse consisted of ZnCl₂ at 6 mM (0.08%), NaCl at 500mM (2.9%) and H2O₂ at 1%.

The oral rinse was tested for its effects on the E_(h) lowering and oralmalodor forming activity of the oral bacteria. The oral malodorformation was assessed organoleptically, measuring VSC using a Halimeter(Model RH-17A Interscan Portable Analyzer) and measuring the formationof indole/skatole using Kovac's method. Gadebusch H. H. and Gabriel S.(1956). “Modified Stable Kovac's Reagent for the Detection of Indole”,Amer. J. Clin. Path. 26, 1373-1375. The organoleptic measurements weredone by having a trained individual smell the odor produced and rate theodor on a scale of 0-4, with zero indicating no malodor and fourindicating strong malodor. In the Kovac method, Kovac's Reagent(P-Dimethylaminobenzaldehyde dissolved in amyl alcohol and acidifiedwith HCl) was added to each assay sample and the bluish/red color wasmeasured at 567 nm in a spectrophotometer.

Experiments were run on subjects who had fasted and carried out no oralhygiene for the last 12 h. Testing was started between approximately 9a.m. and 10 a.m. For the baseline sample, the subject cleared salivafrom the mouth by gentle expectoration and rested for a period of 2minutes to allow fresh saliva to collect. This saliva was then spit intoa test tube chilled in cracked ice. If the collected saliva was lessthan 750 ml a further 2 minute period was used for collection. Followingthe baseline collection, the subject rinsed his/her mouth with 5 ml ofthe test solution for 20 seconds and a saliva sample was collected asabove. The collection once more was for a 2 minute period. Salivasamples were also collected at different times up to four hoursfollowing the rinse. 750 ml of each saliva sample was immediatelyincubated in a 37° C. water bath and the E_(h). odor index, and volatilesulfur compounds (VSC) in each sample were determined at 0, 15 and 30minutes and at 1, 2, 3, 4, 8 and 24 h; these values were averaged togive a mean value assay of each parameter in each sample. Subjects weretested on 3 different days. Day one was without the use of a rinse, daytwo with a water rinse and day three with a zinc-peroxide-chloride ionrinse.

FIG. 4 shows the results after the zinc-hydrogen peroxide-chloride ionrinsing. As shown by this figure, the zinc-hydrogen peroxide-chlorideion composition of the present invention favored a more positive E_(h)level and its effect on odor was dramatic. Odor production determinedorganoleptically and by indole/skatole formation were almost totallyretarded and the production of VSC was significantly reduced. No changesfrom base-line (BL) were seen when water was the rinsing solution or norinsing was done. The oral composition of the present invention affectedthe E_(h) positively and suppressed odor parameters even after 4 hoursfollowing the rinse. Only indole/skatole formation began to return after4 hours. These results demonstrate the ability of the oral compositionsdescribed herein to reduce oral malodor by preventing the ability of theoral bacteria to reduce the E_(h) of the oral cavity.

EXAMPLE IV

The ability of a zinc chloride rinse solution to reduce or prevent theformation of volatile sulfur compounds (VSC) in vivo followingsuccessive challenges with a cysteine rinse was studied in this Example.The rinse solution consisted of zinc chloride at 6 mM (0.08%).Experiments were run on subjects who had fasted and carried out no oralhygiene for at least 12 hours. The subject rinsed his/her mouth with 5ml of a 6 mM cysteine solution for 30 seconds to stimulate substantialVSC production by the oral bacteria This test is analogous to the use ofglucose as a challenge substrate to determine the glycolytic activity ofdental plaque bacteria (Stephan, R. M. 1944. J. dent. Res. 23, 257) oringestion of a fixed amount of glucose as a challenge in assaying fordiabetes activity. Before and following the rinse, a Halimeterinstrument was used to measure the volatile sulfur compounds (VSC)produced. Simultaneously, a platinum electrode was placed on theposterior dorsum surface of the tongue, just anterior to thecircumvallate papillae to measure the E_(h). After 20 minutes, thesubject rinsed his/her mouth with 5 ml of the zinc chloride solution for30 seconds. Again, the VSC of the subject's mouth air and the E_(h) weremeasured. The subject then rinsed successively with the 6 mM cysteinesolution at 40, 60, 140, 320 and 380 minutes and the VSC and E_(h) ofthe subject's oral cavity were re-measured each time (see FIG. 5) usingthe Halimeter and the platinum electrode. As shown in FIG. 5, the zincchloride rinse reduced the ability of the oral bacteria to produce theVSC response to cysteine rinsing and retarded the production of the VSCresponse to subsequent cysteine rinses for about 5 hours thereafter. Thesame figure also shows the E_(h) response that occurs co-incident withthe VSC response after cysteine challenging. The E_(h) was raised to asmall degree during rinsing with the zinc chloride solution. Clearanceof the cysteine by saliva and rapid utilization of the cysteine by theoral bacteria facilitates the removal of the cysteine and the returningof the VSC and to their respective baselines during each cysteinechallenge episode. As demonstrated by this in vivo assay, zinc chlorideis a compound that is able to reduce the ability of the oral bacteria togenerate volatile sulfur compounds. This contributes to reduced oralputrefaction activity and in turn reduced oral malodor production andgingivitis-periodontitis.

EXAMPLE V

The ability of a zinc-hydrogen peroxide-salt composition to reduce orprevent the formation of VSC in vivo following successive challengeswith a cysteine rinse was studied in this Example in the same way as inExample IV. The oral rinse consisted of zinc chloride at 6 mM (0.08%),hydrogen peroxide at 1% and sodium chloride at 500 mM (2.9%). As before,5 ml of the zinc/peroxide/chloride ion composition of this invention wasapplied as a rinse for 30 seconds. VSC and E_(h) measurements were alsocarried out as before and the results are shown in FIG. 6. Thezinc-peroxide-chloride ion rinse of this invention showed greaterinhibition of VSC production and for a longer time than in Example IVwhere the zinc chloride was tested without peroxide and chloride ion.The E_(h) rose strongly and more with the zinc chloride-peroxide-sodiumchloride composition following its application than did zinc chloridealone in Example IV and the subsequent E_(h) responses were initiallyinhibited and return to the baseline response was delayed. This Exampleshows that the oral composition of the present invention is able tosignificantly inhibit VSC production from cysteine and its ability tolower the E_(h), and has the ability to raise the E_(h) when introducedin vivo.

EXAMPLE VI

The ability of a zinc-chloride-sodiun chlorite composition to reduce orprevent the formation of VSC in vivo following successive challengeswith a cysteine rinse was studied in this Example in the same way as inExamples IV and V. The oral rinse consisted of zinc chloride at 6 mM(0.08%) and sodium chlorite at 0.5%. As before, 5 ml of thezinc/peroxide/chloride ion composition of this invention was applied asa rinse for 30 seconds. VSC and E_(h) measurements were also carried outas before and the results are shown in FIG. 7. The zinc-chloride-sodiunchlorite rinse of this invention showed as in Example V, greaterinhibition of VSC production and for a longer time than in Example IVwhere the zinc chloride was tested without sodium chlorite. The E_(h)rose strongly and more with the zinc chloride-sodium chloritecomposition following its application than did zinc chloride alone inExample IV; the subsequent E_(h) responses were initially inhibited andreturn to the baseline response was delayed. This Example shows that theoral composition of the present invention is able to significantlyinhibit VSC production from cysteine and its ability to lower the E_(h),and has the ability to raise the E_(h) upon introduction into the oralcavity.

EXAMPLE VII

The abilities of 0.1% sodium chlorite rinse solutions, one without andone with zinc chloride at 6 mM (0.08%) were compared in this Example fortheir abilities to reduce or prevent the formation of VSC in vivofollowing successive challenges with a cysteine rinse as before. Theoral rinse consisted of application of 5 ml for 30 seconds of either an0.1% sodium chlorite solution or an 0.1% sodium chlorite solution towhich zinc chloride at 0.08% had been added. VSC and E_(h) measurementswere carried out as before and the results are shown in FIGS. 8 and 9.The sodium chlorite showed no inhibition of VSC production (FIG. 8)whereas the zinc chloride-sodiun chlorite combination was inhibitory andmore so than observed for zinc chloride alone (FIG. 5) in Example IV.This Example shows that combining zinc chloride and sodium chlorite canproduce a greater effect than expected from simple addition of theirindividual effects.

We claim:
 1. An oral composition comprising a first component containinga zinc compound which yields freely available zinc ions in a firstvehicle suitable for introduction to the oral cavity and a secondcomponent containing an oxidation potential raising compound in a secondvehicle suitable for introduction to the oral cavity, wherein said firstand second components are stored separately and mixed prior to using theoral composition.
 2. The oral composition of claim 1, wherein the zinccompound ionizes in solution to produce a 0.02% to about 0.2% by weightconcentration of zinc ions in the oral composition and the concentrationof the oxidation potential raising compound in the oral composition isfrom about
 0. 1% to about 3.0% by weight.
 3. The oral composition ofclaim 1, wherein the zinc compound ionizes in solution to produce zincions at a concentration in the oral composition ranging from about 0.04%to about 0.12% by weight.
 4. The oral composition of claim 1, whereinthe concentration of the oxidation potential raising compound in theoral composition ranges from about 0.1% to about 1.0% by weight.
 5. Theoral composition of claim 1, wherein the zinc compound is selected fromthe group consisting of zinc chloride, zinc sulfate, zinc acetate, zinclactate, zinc salicylate, zinc nitrate, and a mixture of two or more ofthe aforementioned zinc compounds.
 6. The oral composition of claim 1,wherein the oxidation potential raising compound is selected from thegroup consisting of hydrogen peroxide, oxyhalogen, methylene blue, and amixture of two or more of the aforementioned oxidation potential raisingcompounds.
 7. The oral composition of claim 1, wherein the oralcomposition is selected from the group consisting of a dental careproduct, a food product, a lozenge, a chewing gum, and a confection. 8.The oral composition of claim 1, wherein the zinc compound is zincchloride and the oxidation potential raising compound is sodiumchlorite.
 9. The oral composition of claim 8, wherein the pH of thefirst component during storage ranges from about 3.0 to about 6.0 andthe pH of the second component during storage ranges from about 7.0 toabout 8.5.
 10. The oral composition of claim 9, wherein the compositionfurther comprises sodium chloride.
 11. The oral composition of claim 1,wherein the oxidation potential raising compound is hydrogen peroxideand wherein the composition further comprises chloride ion at aconcentration from about 0.5% to about 3.1% by weight.
 12. The oralcomposition of claim 11, wherein the composition further comprisessodium chloride.
 13. The oral composition of claim 11, wherein the pH ofthe first component during storage ranges from about 3.0 to about 6.0and the pH of the second component during storage ranges from about 3.0to about 6.0.
 14. An oral composition comprising a first componentcontaining a zinc compound which yeilds freely available zinc ionsselected from the group consisting of zinc chloride, zinc sulfate, zincacetate, zinc lactate, zinc salicylate, zinc nitrate, and a mixture oftwo or more of the aforementioned zinc compounds in a first vehiclesuitable for introduction to the oral cavity and a second componentselected from the group consisting of hydrogen peroxide, oxyhalogen,methylene blue, and a mixture of two or more of hydrogen peroxide,oxyhalogen, methylene blue, and sodium chloride in a second vehiclesuitable for introduction to the oral cavity, wherein said first andsecond components are stored separately and mixed prior to using theoral composition.
 15. The oral composition of claim 14, wherein the zinccompound is zinc chloride and the second component is sodium chloride.16. The oral composition of claim 15, further comprising sodiumchlorite.
 17. The oral composition of claim 16, further comprising a pHbuffer.
 18. The oral composition of claim 17, wherein the pH buffermaintains the pH of the sodium chlorite at between about 7.0 and 8.5.19. The oral composition of claim 17, wherein the concentration of thesodium chlorite in the oral composition ranges from about 0.1% to about1.0% by weight.
 20. The oral composition of claim 17, wherein theconcentration of the chloride ion in the oral composition ranges fromabout 0.5% to about 3.1% by weight.
 21. A method for inhibiting theformation of sulfur containing anions in the oral cavity and preventinga reduction of the oxidation potential of the oral cavity comprisingdelivering into the oral cavity a therapeutically effective amount of anoral composition, wherein the oral composition comprises a firstcomponent containing a zinc compound which yields freely available zincions in a first vehicle suitable for introduction to the oral cavity anda second component containing an oxidation potential raising compound ina second vehicle suitable for introduction to the oral cavity, whereinsaid first and second components are stored separately and mixed priorto using the oral composition.
 22. The method of claim 21, wherein thezinc compound ionizes in solution to produce a concentration of zincions in the oral composition ranging from about 0.02% to about 0.2% byweight, and wherein the concentration of the oxidation potential raisingcompound in the oral composition is from about 0.1% to about 3.0% byweight.
 23. The method of claim 21, wherein the zinc compound ionizes insolution to produce zinc ions at a concentration in the oral compositionranging from about 0.04% to about 0.12% by weight.
 24. The method ofclaim 21, wherein the concentration of the oxidation potential raisingcompound in the oral composition ranges from about 0.1% to about 1.0% byweight.
 25. The method of claim 21, wherein the zinc compound isselected from the group consisting of zinc chloride, zinc sulfate, zincacetate, zinc lactate, zinc salicylate, zinc nitrate, and a mixture oftwo or more of the aforementioned zinc compounds.
 26. The method ofclaim 21, wherein the oxidation potential raising compound is selectedfrom the group consisting of hydrogen peroxide, oxyhalogen, methyleneblue, and a mixture of two or more the aforementioned oxidationpotential raising compounds.
 27. The method of claim 21, wherein theoral composition is selected from the group consisting of a dental careproduct, a food product, a lozenge, a chewing gum or a confection. 28.The method of claim 21, wherein the zinc compound is zinc chloride andthe oxidation potential raising compound is sodium chlorite.
 29. Themethod of claim 28, wherein the pH of the first component during storageranges from about 3.0 to about 6.0 and the pH of the second componentduring storage ranges from about 7.0 to about 8.5.
 30. The method ofclaim 28, wherein the composition further comprises sodium chloride. 31.The method of claim 21, wherein the oxidation potential raising compoundis hydrogen peroxide and wherein the composition contains chloride ionat a concentration from about 0.5% to about 3.1% by weight.
 32. Themethod of claim 31, wherein the composition contains sodium chloride.33. The method of claim 31, wherein the pH of the zinc compound duringstorage ranges from about 3.0 to about 6.0 and the pH of the hydrogenperoxide during storage ranges from about 3.0 to about 6.0.
 34. A methodfor reducing oral malodor comprising delivering into the oral cavity atherapeutically effective amount of an oral composition, wherein theoral composition comprises a first component containing a zinc compoundwhich yields freely available zinc ions in a first vehicle suitable forintroduction to the oral cavity and a second component containing anoxidation potential raising compound in a second vehicle suitable forintroduction to the oral cavity, wherein said first and secondcomponents are stored separately and mixed prior to using the oralcomposition.
 35. A method of treating gingivitis-periodontitiscomprising delivering into the oral cavity a therapeutically effectiveamount of an oral composition, wherein the oral composition comprises afirst component containing a zinc compound which yields freely availablezinc ions in a first vehicle suitable for introduction to the oralcavity and a second component containing an oxidation potential raisingcompound in a second vehicle suitable for introduction to the oralcavity, wherein said first and second components are stored separatelyand mixed prior to using the oral composition.
 36. A kit comprising: a.a first aqueous solution containing a zinc compound which yields freelyavailable zinc ions; and b. a second aqueous solution containing anoxidation potential raising compound stored separately from the firstaqueous solution, wherein the first aqueous solution and the secondaqueous solution are adapted to be mixed together to provide an oralcomposition, suitable for introduction to the oral cavity.
 37. The kitof claim 36, wherein the zinc compound ionizes to produce a zinc ionconcentration ranging from about 0.02% to about 0.2% by weight in thefirst aqueous solution, and wherein the concentration of the oxidationpotential raising compound in the second aqueous solution is from about0.1% to about 3.0% by weight.
 38. The kit of claim 36, wherein the zinccompound ionizes to produce a concentration of zinc ions in the firstaqueous solution ranging from about 0.04% to about 0.12% by weight. 39.The kit of claim 36, wherein the concentration of the oxidationpotential raising compound in the second aqueous solution ranges fromabout
 0. 1% to about 1.0% by weight.
 40. The kit of claim 36, whereinthe zinc compound is selected from the group consisting of zincchloride, zinc sulfate, zinc acetate, zinc lactate, zinc salicylate,zinc nitrate, and a mixture of two or more of the aforementioned zinccompounds.
 41. The kit of claim 36, wherein the oxidation potentialraising compound is selected from the group consisting of hydrogenperoxide, oxyhalogen, methylene blue, and a mixture of two or more ofthe aforementioned oxidation potential raising compounds.
 42. The kit ofclaim 36, wherein the zinc compound is zinc chloride and the oxidationpotential raising compound is sodium chlorite.
 43. The kit of claim 42,wherein the pH of the first aqueous solution during storage ranges fromabout 3.0 to about 6.0 and the pH of the second aqueous solution duringstorage ranges from about 7.0 to about 8.5.
 44. The kit of claim 36,wherein the oxidation potential raising compound is hydrogen peroxideand wherein the second aqueous solution contains a chloride ion at aconcentration from about 0.5% to about 3.1% by weight.
 45. The kit ofclaim 44, wherein the second aqueous solution contains sodium chloride.46. The kit of claim 44, wherein the pH of the first aqueous solutionduring storage ranges from about 3.0 to about 6.0 and the pH of thesecond aqueous solution during storage ranges from about 3.0 to about6.0.
 47. The kit of claim 44, wherein the first and second aqueoussolutions are present in approximately equal amounts.